Mcrae Capital Management Inc. Boosts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

robot
Abstract generation in progress

Mcrae Capital Management Inc. increased its stock holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 8.9% in the third quarter, making it the 17th biggest position for the firm. Other institutional investors also adjusted their stakes in VRTX, while company insiders sold a significant number of shares. Analysts currently rate Vertex Pharmaceuticals as a “Moderate Buy” with an average target price of $542.00.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin